QuickLinks -- Click here to rapidly navigate through this document
Exhibit 15.1
XYRATEX LTD
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
| Balance at beginning of period | Charged to costs and expenses | Acquisition | Charged to other accounts | Deductions | Balance at end of period | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (US dollars in thousands) | ||||||||||||||||||
Year ended November 30, 2004 | |||||||||||||||||||
Deferred tax valuation allowance | $ | 6,070 | — | — | $ | (1,800 | ) | — | $ | 4,270 | |||||||||
Warranty provision | $ | 1,231 | $ | 1,561 | $ | 508 | — | $ | (1,381 | ) | $ | 1,919 | |||||||
Allowance for doubtful accounts | $ | 371 | $ | 50 | — | — | $ | (223 | ) | $ | 198 | ||||||||
Year ended November 30, 2003 | |||||||||||||||||||
Deferred tax valuation allowance | $ | 17,684 | — | — | $ | (11,614 | ) | — | $ | 6,070 | |||||||||
Warranty provision | $ | 920 | $ | 1,291 | — | — | $ | (980 | ) | $ | 1,231 | ||||||||
Allowance for doubtful accounts | $ | 583 | $ | 22 | — | — | $ | (234 | ) | $ | 371 | ||||||||
Year ended November 30, 2002: | |||||||||||||||||||
Deferred tax valuation allowance | $ | 11,659 | — | — | $ | 6,025 | — | $ | 17,684 | ||||||||||
Warranty provision | $ | 560 | $ | 920 | — | — | $ | (560 | ) | $ | 920 | ||||||||
Allowance for doubtful accounts | $ | 327 | $ | 540 | — | — | $ | (284 | ) | $ | 583 |
Note: The schedule of Valuation and Qualifying Accounts previously filed in relation to the 2003 financial year does not appropriately reflect the amounts included in the underlying accounting records of the Company. Consequently, the deferred tax valuation allowances at November 30, 2003 and 2002 have been changed to $6,070 and $17,684 from $4,270 and $16,168, respectively, and, the amounts charged/(credited) to Other Accounts in 2003 and 2002 have been changed to ($11,614) and $6,025 from ($11,898) and $4,509, respectively, to agree to the underlying accounting records of the Company and to be consistent with the financial statement presentation.
The information above relates to the continuing operations of the Company.
XYRATEX LTD SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES